24 Jun 2020 Update - Web Training Program

23 Apr 2020

Contents of the Web Training Program

OWLPHARMA has prepared a Web training program featuring several Quality Assurance, Regulatory Affairs and Pharmacovigilance contents.

15 Apr 2020

Web Training Program

OWLPHARMA has developed a Web training program covering Pharmacovigilance, Regulatory Affairs and several GxPs contents.

27 Mar 2020

OFF-SITE AUDITS

Following the current COVID-19 pandemic, and in order to maintain the state of compliance and ensure fulfillment of GxP requirements, companies must now find alternatives to continue the qualification process of their sources.

26 Mar 2020

NITROSAMINES – RISK EVALUATION EXTENDED TO OCTOBER 2020

EMA has published an update on their website extending the completion date for the risk assessment of nitrosamines – step 1. The new submission deadline is the 1st of October 2020, more information is expected to be published tomorrow.

16 Mar 2020

COVID-19 - Business Continuity Plan Activation

Following recent developments and immediately after WHO announcement of COVID-19 virus outbreak classification as a pandemic, OWLPHARMA has decided to activate its business continuity plan.

21 Feb 2020

Safety Assessment of Cosmetic Products

Regulation (EC) no. 1223/2009 stipulates that all cosmetic products, prior to being marketed in the EU, must undergo a safety assessment carried out by a qualified person. The assessment must always be kept up to date, and any relevant information generated after the product is placed on the market has to be taken into account.